Aclaris Therapeutics Shares Rise After FDA Clear ATI-052 for Trial

Published: 2025-04-22 08:22:07 ET ACRS

By Dean Seal

Shares of Aclaris Therapeutics were trading higher after the company said regulators had cleared its new drug application for a trial of ATI-052, its potential treatment for immuno-inflammatory diseases.

The stock was up 10% at $1.25 in premarket trading. Shares were trading at around this price 12 months ago.

The clinical-stage biopharmaceutical company said Tuesday that the U.S. Food and Drug Administration has cleared its investigational new drug application for a Phase 1a/1b clinical trial of ATI-052.

The trial will evaluate single and multiple ascending doses of ATI-052 and then a proof-of-concept portion in an undisclosed indication. The trial is expected to start up in the second quarter.

Write to Dean Seal at [email protected]

(END) Dow Jones Newswires

04-22-25 0821ET